KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EBT (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed EBT for 18 consecutive years, with $831.2 million as the latest value for Q1 2026.

  • For Q1 2026, EBT fell 8.15% year-over-year to $831.2 million; the TTM value through Mar 2026 reached $5.2 billion, up 3.46%, while the annual FY2025 figure was $5.2 billion, 9.43% up from the prior year.
  • EBT hit $831.2 million in Q1 2026 for Regeneron Pharmaceuticals, down from $1.0 billion in the prior quarter.
  • Across five years, EBT topped out at $1.8 billion in Q3 2025 and bottomed at $700.7 million in Q1 2024.
  • Average EBT over 5 years is $1.2 billion, with a median of $1.1 billion recorded in 2023.
  • Year-over-year, EBT tumbled 74.33% in 2022 and then soared 50.35% in 2024.
  • Regeneron Pharmaceuticals' EBT stood at $1.3 billion in 2022, then dropped by 13.37% to $1.1 billion in 2023, then dropped by 16.51% to $958.1 million in 2024, then increased by 8.93% to $1.0 billion in 2025, then decreased by 20.36% to $831.2 million in 2026.
  • According to Business Quant data, EBT over the past three periods came in at $831.2 million, $1.0 billion, and $1.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.